Form 8-K Immunovant, Inc. For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Citi Reiterates Buy Rating on Immunovant (IMVT)
March 20, 2025 6:07 AM EDTCiti analyst Samantha Semenkow reiterated a Buy rating and $58.00 price target on Immunovant (NASDAQ: IMVT).
The analyst comments "Following yesterdays release of topline gMG data (see our take here), the most frequent piece of pushback weve received from investors is that... More
